You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Clinical features of patients with MRSA bacteraemia associated with survivor and non-survivora

From: Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units

  Survivor (n = 13) Non-survivor (n = 35) p value
Patient demographics    
 Median age (years) 76.5 ± 11.5 67.8 ± 18.2 0.114
 Male sex 7 20 0.838
hVISA 1 13 0.046
Charlson comorbidity score 2.4 ± 1.4 3.2 ± 2.1 0.207
SOFA score 5.9 ± 3.0 9.1 ± 3.8 0.009
Hemodialysis 2 19 0.016
Comorbidity    
 Chronic renal disease 3 (23.1) 15 (42.9) 0.208
 Solid organ malignancy 2 6 0.885
 Hematological malignancy 0 2 0.379
 Diabetes mellitus 7 11 0.154
 Liver cirrhosis 1 8 0.232
 Heart disease 3 6 0.640
 Chronic pulmonary disease 0 2 0.379
 Cerebrovascular accident 7 5 0.005
Primary site of infection    0.72
 Catheter-related infection 3 4  
 Pneumonia 6 18  
 Surgical wound infection 1 2  
 Other 0 3  
 Unknown 3 8  
CRP 139.5 ± 84.7 135.6 ± 88.5 0.897
Albumin 2.6 ± 0.8 2.4 ± 0.5 0.425
Prior vancomycin therapy 4 11 0.627
Adequate antibiotics treatment 3 12 0.48
Shock after infection 2 15 0.077
agr dysfunction 1 (7.7) 12 (34.3) 0.065
Vancomycin MIC (Etest)    0.111
 1 mg/L 1 5  
 1.5 mg/L 8 10  
 2 mg/L 4 20  
  1. aAll values presented as number (%) or mean value ± SD unless otherwise indicated
  2. CRP C-reactive protein